1. Home
  2. USNA vs DCTH Comparison

USNA vs DCTH Comparison

Compare USNA & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • USNA
  • DCTH
  • Stock Information
  • Founded
  • USNA 1992
  • DCTH 1988
  • Country
  • USNA United States
  • DCTH United States
  • Employees
  • USNA N/A
  • DCTH N/A
  • Industry
  • USNA Medicinal Chemicals and Botanical Products
  • DCTH Medical/Dental Instruments
  • Sector
  • USNA Health Care
  • DCTH Health Care
  • Exchange
  • USNA Nasdaq
  • DCTH Nasdaq
  • Market Cap
  • USNA 565.2M
  • DCTH 394.9M
  • IPO Year
  • USNA 1996
  • DCTH N/A
  • Fundamental
  • Price
  • USNA $29.52
  • DCTH $10.93
  • Analyst Decision
  • USNA Hold
  • DCTH Strong Buy
  • Analyst Count
  • USNA 1
  • DCTH 4
  • Target Price
  • USNA $36.00
  • DCTH $24.00
  • AVG Volume (30 Days)
  • USNA 129.4K
  • DCTH 709.1K
  • Earning Date
  • USNA 07-22-2025
  • DCTH 08-06-2025
  • Dividend Yield
  • USNA N/A
  • DCTH N/A
  • EPS Growth
  • USNA N/A
  • DCTH N/A
  • EPS
  • USNA 1.79
  • DCTH N/A
  • Revenue
  • USNA $899,221,000.00
  • DCTH $53,850,000.00
  • Revenue This Year
  • USNA $13.94
  • DCTH $162.10
  • Revenue Next Year
  • USNA $6.51
  • DCTH $32.97
  • P/E Ratio
  • USNA $16.86
  • DCTH N/A
  • Revenue Growth
  • USNA 2.75
  • DCTH 1068.87
  • 52 Week Low
  • USNA $23.10
  • DCTH $7.17
  • 52 Week High
  • USNA $45.86
  • DCTH $18.23
  • Technical
  • Relative Strength Index (RSI)
  • USNA 42.00
  • DCTH 33.70
  • Support Level
  • USNA $30.10
  • DCTH $11.15
  • Resistance Level
  • USNA $38.32
  • DCTH $11.67
  • Average True Range (ATR)
  • USNA 1.34
  • DCTH 0.60
  • MACD
  • USNA -0.30
  • DCTH 0.06
  • Stochastic Oscillator
  • USNA 0.96
  • DCTH 5.72

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: